Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA.
Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Pharmacogenomics. 2024 Jan;25(1):29-40. doi: 10.2217/pgs-2023-0204. Epub 2024 Jan 8.
Successful treatment with tacrolimus to prevent graft versus host disease (GVHD) and minimize tacrolimus-related toxicities among allogeneic hematopoietic cell transplantation (alloHCT) recipients is contingent upon quickly achieving and maintaining concentrations within a narrow therapeutic range. The primary objective was to investigate associations between or genotype and the proportion of patients that attained an initial tacrolimus goal concentration following initiation of intravenous (iv.) and conversion to oral administration. We retrospectively evaluated 86 patients who underwent HLA-matched (8/8) related donor alloHCT and were prescribed a tacrolimus-based regimen for GVHD prophylaxis. The findings of the present study suggests that genotype may impact attainment of initial therapeutic tacrolimus concentrations with oral administration in alloHCT recipients.
成功使用他克莫司预防移植物抗宿主病 (GVHD) 并最小化同种异体造血细胞移植 (alloHCT) 受者的他克莫司相关毒性取决于迅速达到并维持窄治疗范围内的浓度。主要目的是研究 或 基因型与静脉 (iv.) 起始和转换为口服给药后达到初始他克莫司目标浓度的患者比例之间的关联。我们回顾性评估了 86 例接受 HLA 匹配 (8/8) 相关供体 alloHCT 并接受基于他克莫司的 GVHD 预防方案的患者。本研究的结果表明，基因型可能会影响 alloHCT 受者口服初始治疗性他克莫司浓度的获得。
